Expanded collaboration helps remove barriers and enables more programs to advance toward the clinic by improving and accelerating access to critical analytical and GMP biosafety testing.
Genezen, a best-in-class viral vector contract development and manufacturing organization (CDMO), is pleased to announce an expanded collaboration with SGS, a global leader in biopharmaceutical testing. As part of an initiative designed to help advance viral vector manufacturing for patient-led and foundation-supported programs, SGS will provide Genezen’s clients with outsourced GMP biosafety and analytical testing services.
These programs, often funded by parents, families, and patient advocacy foundations, represent some of the most urgent and impactful work in gene therapy. By improving and accelerating access to critical analytical and biosafety testing, this collaboration helps remove barriers and enables more programs to advance toward the clinic.
Through this partnership, Genezen clients will gain access to SGS’s comprehensive suite of GMP-compliant biosafety and characterization services, spanning early-phase development through clinical and commercial release. SGS’s laboratories in Glasgow (UK) and Lincolnshire (US) provide more than 300 validated assays and supports a wide range of modalities, including viral vectors, cell and gene therapies, and vaccines, all performed in accordance with global regulatory standards.
“Foundation-supported programs are some of the most meaningful and time-sensitive initiatives in our industry,” said Susan D’Costa, Genezen’s Chief Technical and Chief Commercial Officer. “By partnering with SGS to streamline access to critical testing services, we’re helping ensure these programs can move forward with greater speed, efficiency, and confidence.”
“Collaborating with Genezen allows us to support programs that are not only scientifically complex, but deeply meaningful,” said Mike Pipis, MSc, Head of Sales – Biosafety for SGS North America. “We are proud to provide dedicated, mission-driven support that helps remove barriers and accelerate progress for patients and families.”
“The sense of urgency and commitment to innovation from both the Genezen and SGS teams is palpable,” said Tiffany Sepp, Development Team Leader for The Charlotte and Gwenyth Gray Foundation to Cure Batten Disease, the first organization to benefit from the collaboration. “We all know, we all feel, we all are committed – these kiddos can’t wait. And these talented teams share our perspectives on the rare disease families we all work tirelessly to serve. The entire Charlotte & Gwenyth Gray Foundation is left with an impression that will not soon be forgotten.”
As a global leader in biopharmaceutical testing with deep expertise in biologics, SGS has a proven track record of supporting biopharmaceutical manufacturers from early development through batch release. Their biosafety center features advanced laboratory infrastructure and a team of experienced scientists dedicated to delivering high-quality, reliable results.
The partnership reflects a shared commitment to advancing gene therapy programs that may not follow traditional commercial pathways but are critical to addressing rare and life-threatening diseases. Combining Genezen’s expertise in viral vector manufacturing with SGS’s industry-leading testing capabilities enables the delivery of an integrated solution that improves efficiency and development challenges.
As demand for gene therapies continues to grow, particularly among foundation-backed and early-stage programs, partnerships like this play a critical role in enabling broader access to high-quality manufacturing and testing infrastructure.
About Genezen
Genezen is a best-in-class gene therapy CDMO with over 12 years of experience and state-of-the-art viral vector manufacturing facilities. From concept to commercial scale, Genezen partners with innovators to deliver life-saving gene and cell therapies worldwide. Learn more at genezen.com or follow Genezen on LinkedIn.
About SGS
SGS is the world’s leading Testing, Inspection and Certification company. We operate a network of over 2,500 laboratories and business facilities across 115 countries, supported by a team of over 100,000 dedicated professionals. With more than 145 years of service excellence, we combine the precision and accuracy that define Swiss companies to help organization achieve the highest standards of quality, compliance and sustainability.
Our brand promise – when you need to be sure – underscores our commitment to trust, integrity and reliability, enabling businesses to thrive with confidence. We proudly deliver our expert services through the SGS name and a portfolio of trusted specialized brands, including Applied Technical Services, Brightsight, Bluesign and Nutrasource.
SGS is publiced traded on the SIX Swiss Exchange under the ticker symbol SGSN (ISIN CH1256740924, Reuters SGSN.S, Bloomberg SGSN SW).
About The Charlotte & Gwenyth Gray Foundation to Cure Batten Disease
The Charlotte and Gwenyth Gray Foundation exists to improve and save the lives of all children impacted by Batten disease and other neurodegenerative disorders. Founded by two parents committed to finding a cure for Batten Disease to save the lives of their daughters, the Foundation recognizes firsthand the day-to-day challenges of living with a rare disease. In addition to funding research, the Foundation also provides financial support to families for education, patient therapies, and equipment critical to their well-being and rehabilitation. For more information and to support this cause, please visit www.curebatten.org
